Previous studies suggested that the up-regulation of complement regulation proteins (CRPs) such as CD55 and CD59 on surface of lymphoma cells inhibits the activation of complement systems, which might be the main cause of resistant cells’ unresponsiveness to Rituximab mediated CDC in vitro [43, 44]. The gene discussed is CD55; the disease is lymphoma.